Virtu Financial’s Dermata Therapeutics Warrant DRMAW Stock Holding History

Virtu Financial’s Portfolio DRMAW Stock Details DRMAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,856	Closed	–	–	1598
2025 Q2	$0	Buy	+10,856	New	+$201	﹤0.01%	1606
2022 Q2	–	Sell	-18,171	Closed	-$3K	–	1689
2022 Q1	$3K	Buy	+18,171	New	+$5.14K	﹤0.01%	1407

Other funds holding DRMAW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Virtu Financial's DRMAW Position: Q3 2025 in Review

Virtu Financial sold out of Dermata Therapeutics Warrant (DRMAW) in Q3 2025, closing a stake of 10,856 shares.

Virtu Financial first reported a position in DRMAW in Q1 2022 and held it in 2 quarters. The position peaked at $3K in Q1 2022. 3 funds tracked by Wall St. Rank hold DRMAW as of Q3 2025.

Virtu Financial reported no remaining Dermata Therapeutics Warrant position as of Q3 2025 after selling out during the quarter.
Virtu Financial sold 10,856 Dermata Therapeutics Warrant shares in Q3 2025.
Virtu Financial first reported a position in Dermata Therapeutics Warrant in Q1 2022 and held it in 2 quarters.
Virtu Financial's Dermata Therapeutics Warrant position peaked at $3K in Q1 2022.
3 funds tracked by Wall St. Rank held Dermata Therapeutics Warrant as of Q3 2025.

Based on Virtu Financial's 13F filing for Q3 2025, filed 14 Nov 2025.